Theravance Inc.'s antibiotic telavancin, deemed approvable earlier this year in complicated skin and skin structure infections caused by Gram-positive bacteria, achieved its endpoint in a second pivotal program in hospital-acquired pneumonia (HAP) patients. (BioWorld Today) Read More
